Healthy volunteers test new drug for brain disease clues
NCT ID NCT06625710
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety of a drug called GV1001 in 59 healthy adults. Participants received either a single dose or multiple doses of the drug or a placebo. The goal was to see if the drug is safe and how the body processes it, not to treat any disease. Results will help plan future studies for neurodegenerative conditions like Alzheimer's.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEURO-DEGENERATIVE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI reveal the Brain's response to deep brain stimulation?
- Could sharing lived experiences ease the burden of dementia care?
- Scientists watch brain activity as stroke survivors walk and think
- One million volunteers join quest to decode aging
- Italian swallowing assessment tool validated for neurodegenerative patients
- New ALS drug trial aims to tame inflammation